United States: Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK In Lupus Nephritis - Goodwin Procter LLP

On February 22, 2024, Artiva announced that the FDA has granted Fast Track designation to Artiva's AlloNK (AB-101) for the treatment of lupus nephritis in combination with rituximab or obinutuzumab...